Asselah T, et al. - This study was performed to investigate the efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus (HCV) genotype 2, 4, 5, or 6 infection without cirrhosis in 3 separate phase 3 trials. With virologic failure in less than 1%, eight weeks’ treatment with glecaprevir/pibrentasivr produced an sustained virologic response at 12 weeks after treatment (SVR12) in at least 93% of patients with chronic HCV genotype 2, 4, 5, or 6 infection without cirrhosis in 3 Phase 3 studies. The drug combination had a safety profile comparable to 12 week’s treatment with glecaprevir/pibrentasvir.